Last reviewed · How we verify
Glutamate (GLUTAMIC ACID)
Glutamic Acid, a marketed nutritional support for infants and young children, holds a position in a niche but essential market segment. Its key strength lies in its mechanism of action, which involves binding to and activating glutamate receptors in the brain, aiding in the regulation of various physiological processes. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | GLUTAMIC ACID |
|---|---|
| Drug class | Amino Acid [EPC] |
| Target | Glutamate dehydrogenase 1, mitochondrial, Glutamate dehydrogenase 2, mitochondrial, Metabotropic glutamate receptor 6 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Nutritional Support for Infants and Young Children
- Prevent Nitrogen and Weight Loss
Common side effects
- Metabolic acidosis
- Alkalosis
- Osmotic diuresis and dehydration
- Rebound hypoglycemia
- Hypo- and hyper-vitaminosis
- Pulmonary embolism due to pulmonary vascular precipitates
- Hypersensitivity reactions
- Risk of infections
- Refeeding syndrome
- Hyperglycemia or hyperosmolar hyperglycemic state
- Vein damage and thrombosis
- Hepatobiliary disorders
Key clinical trials
- Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones (PHASE1)
- MRS Measurement of Glutamate and GABA Metabolism in Brain (NA)
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin (PHASE1,PHASE2)
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma (PHASE1,PHASE2)
- Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection (PHASE1)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |